<DOC>
	<DOCNO>NCT00812565</DOCNO>
	<brief_summary>This study evaluate effect 6 12 infusion different dos octagam ( intravenous immunoglobulin [ IVIG ] ) 10 % reduction amyloid beta peptide ( Aβ ) cerebral spinal fluid ( CSF ) increase Aβ blood plasma patient mild moderate Alzheimer 's disease .</brief_summary>
	<brief_title>Study Octagam ( Intravenous Immunoglobulin IVIG ) 10 % Treatment Mild Moderate Alzheimer 's Disease</brief_title>
	<detailed_description>Participants receive 12 infusion 0.1 g/kg , 0.25 g/kg , 0.4 g/kg body weight octagam 10 % 2-week interval ( ±3 day ) 6 infusion 0.2 g/kg , 0.5 g/kg , 0.8 g/kg body weight octagam 10 % 4-week interval ( ±5 day ) . The effect infusion reduction Aβ peptide CSF increase Aβ peptide blood plasma evaluate .</detailed_description>
	<mesh_term>Alzheimer Disease</mesh_term>
	<mesh_term>Immunoglobulins , Intravenous</mesh_term>
	<mesh_term>gamma-Globulins</mesh_term>
	<mesh_term>Rho ( D ) Immune Globulin</mesh_term>
	<mesh_term>Immunoglobulins</mesh_term>
	<mesh_term>Antibodies</mesh_term>
	<criteria>Probable Alzheimer 's Disease ( AD ) accord National Institute Neurological Communicative Disorders Stroke Alzheimer 's Disease Related Disorders Association ( NINCDSADRDA ) criterion . Age 50 85 . Minimental State Examination ( MMSE ) score 16 26 . Sufficient language skill test . Sufficient vision hear test . Modified HachinskiRosen Score &lt; 5 . Magnetic resonance imaging ( MRI ) head consistent diagnosis AD . Caregiver available contact least 4 day per week great 1 hour . Outpatient status assist living . Postmenopause ( woman ) evidence lack menstruation least 12 consecutive month bilateral oophorectomy . Stable dos approve AD medication ( ) least 3 month prior screen ( eg , acetylcholine esterase ( AChE ) inhibitor , memantine ) . Normal vital sign clinically insignificant , outside normal limit . Laboratory finding within normal limit clinically insignificant , outside normal limit . Normal electrocardiogram ( ECG ) clinically significant , outside normal limit . Other cause dementia ( eg , vascular dementia , Lewybody dementia , frontotemporal dementia , CreutzfeldtJacob disease , Huntington 's disease , Parkinson 's disease ) . History present significant diseases central nervous system ( eg , brain tumor , normal pressure hydrocephalus , Parkinson 's Disease , stroke , severe brain trauma , brain surgery , epilepsy , encephalitis ) . Geriatric depression scale score &gt; 7 ( short form scale 0 15 ) . Present significant psychiatric disorder ( eg , major depression ) . History psychosis hallucination . Mental retardation . Unstable medical disease opinion investigator . Insulin dependent diabetes mellitus . Acute infectious disease . Vitamin B12 deficiency unless stable replacement therapy least 3 month acceptable . Unstable thyroid dysfunction . Uncontrolled hypertension . Severe liver kidney disease . Major surgery within 3 month prior screen . Prohibited medication : Antiepileptic drug , antipsychotic ( allow treatment acute episode ) , antiparkinson agent , anticholinergic drug , selegiline , monoamine oxidase inhibitor ( MAOI ) , tricyclic , immunosuppressive medication , antihistamine ( unless stable dose least 3 month use treatment acute episode ) , benzodiazepine ( allow treatment acute episode ) , lithium . Antidepressants permit , stable dose least 3 month without significant anticholinergic sideeffects . Peripheral venous condition impair establish regular venous access infusion . Potential reason patient may become nonevaluable study ( eg , plan move nursing home , assist live acceptable ) . Peripheral venous condition , impair establish regular venous access infusion . Known IgA deficiency antibody IgA . History hypersensitivity blood plasma derive product , component octagam 10 % , maltose . Medical condition interfere protein catabolism ( eg , nephrotic syndrome ) . Known blood hyperviscosity hypercoagulable state . Deep vein thrombosis within precede 4 year . Symptomatic stroke . Transient ischemic attack ( TIA ) within precede 2 year . Participation another drug trial within previous 3 month screen . Participation immunological treatment study AD intravenous immunoglobulin ( IGIV ) within previous 6 month screen . IGIV use previous 6 month . Live viral vaccination within last month study entry . Not eligible lumbar puncture ( anticoagulant therapy , coagulation disorder , severe spinal alteration ) . Patients past present history drug abuse alcohol abuse within precede 5 year . Patients condition would make patient , opinion Investigator , unsuitable study .</criteria>
	<gender>All</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>April 2014</verification_date>
</DOC>